Justyna Kocik-Krol

1.2k total citations
18 papers, 800 citations indexed

About

Justyna Kocik-Krol is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Justyna Kocik-Krol has authored 18 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 5 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Justyna Kocik-Krol's work include Cancer Immunotherapy and Biomarkers (13 papers), CAR-T cell therapy research (11 papers) and Peptidase Inhibition and Analysis (6 papers). Justyna Kocik-Krol is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), CAR-T cell therapy research (11 papers) and Peptidase Inhibition and Analysis (6 papers). Justyna Kocik-Krol collaborates with scholars based in Poland, Netherlands and Hungary. Justyna Kocik-Krol's co-authors include Tad A. Holak, Łukasz Skalniak, Katarzyna Magiera‐Mularz, Bogdan Musielak, Dominik Sala, Jacek Plewka, P. Grudnik, Alexander Dömlingꝉ, Grzegorz Dubin and Maciej Siedlar and has published in prestigious journals such as Angewandte Chemie International Edition, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

In The Last Decade

Justyna Kocik-Krol

16 papers receiving 788 citations

Peers

Justyna Kocik-Krol

ONCOL

IMMUN

RNMI

Dominik Sala Poland

Marcin D. Tomala Poland

Haiyan Cai China

Wilson Phung United States

T. Ekblad Sweden

Luca Licata Italy

Göran Dahl Sweden

David Xu United States

Luwei Liu United States

Dominik Sala Poland

Justyna Kocik-Krol

385 ×0.6

ONCOL

180 ×0.7

IMMUN

137 ×0.6

82 ×0.7

RNMI

67 ×0.8

Citations per year, relative to Justyna Kocik-Krol Justyna Kocik-Krol (= 1×) peers Dominik Sala

Countries citing papers authored by Justyna Kocik-Krol

Since Specialization

Citations

This map shows the geographic impact of Justyna Kocik-Krol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justyna Kocik-Krol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justyna Kocik-Krol more than expected).

Fields of papers citing papers by Justyna Kocik-Krol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justyna Kocik-Krol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justyna Kocik-Krol. The network helps show where Justyna Kocik-Krol may publish in the future.

Co-authorship network of co-authors of Justyna Kocik-Krol

This figure shows the co-authorship network connecting the top 25 collaborators of Justyna Kocik-Krol. A scholar is included among the top collaborators of Justyna Kocik-Krol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justyna Kocik-Krol. Justyna Kocik-Krol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kocik-Krol, Justyna, Bogdan Musielak, Małgorzata Stec, et al.. (2025). Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy. ACS Medicinal Chemistry Letters. 16(7). 1359–1364.

Statkiewicz, Małgorzata, Alicja Majewska, Justyna Kocik-Krol, et al.. (2025). Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model. Biomedicine & Pharmacotherapy. 193. 118868–118868.

Earnshaw, David L., Ewelina Kaniuga, Małgorzata Statkiewicz, et al.. (2024). Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3DIn VitroCultures. Anticancer Research. 44(10). 4219–4224. 1 indexed citations

Butera, Roberto, Marta Requesens, Annechien Plat, et al.. (2023). Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors. Journal of Medicinal Chemistry. 66(14). 9577–9591. 9 indexed citations

Surmiak, Ewa, Jacek Plewka, Justyna Kocik-Krol, et al.. (2023). Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m-Terphenyl Derivatives. ACS Medicinal Chemistry Letters. 15(1). 36–44. 7 indexed citations

Shaabani, Shabnam, Ewa Surmiak, Roberto Butera, et al.. (2022). Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Molecules. 27(11). 3454–3454. 5 indexed citations

Surmiak, Ewa, Jacek Plewka, Katarzyna Magiera‐Mularz, et al.. (2021). Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction. Journal of Medicinal Chemistry. 64(15). 11614–11636. 61 indexed citations

Surmiak, Ewa, Katarzyna Magiera‐Mularz, Bogdan Musielak, et al.. (2021). PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action. International Journal of Molecular Sciences. 22(21). 11797–11797. 27 indexed citations

Musielak, Bogdan, Justyna Kocik-Krol, Łukasz Skalniak, et al.. (2020). Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Journal of Medicinal Chemistry. 63(19). 11271–11285. 58 indexed citations

10.

Magiera‐Mularz, Katarzyna, Justyna Kocik-Krol, Bogdan Musielak, et al.. (2020). Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience. 24(1). 101960–101960. 58 indexed citations

11.

Magiera‐Mularz, Katarzyna, Łukasz Skalniak, P. Grudnik, et al.. (2020). Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint. Advanced Therapeutics. 4(2). 8 indexed citations

12.

Musielak, Bogdan, Justyna Kocik-Krol, Łukasz Skalniak, et al.. (2019). CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 24(15). 2804–2804. 122 indexed citations

13.

Kocik-Krol, Justyna, et al.. (2019). Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers. 11(7). 1014–1014. 28 indexed citations

14.

Skalniak, Łukasz, Justyna Kocik-Krol, Anna Skalniak, et al.. (2018). Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells. Cancers. 10(11). 396–396. 51 indexed citations

15.

Skalniak, Łukasz, Justyna Kocik-Krol, Katarzyna Guzik, Grzegorz Dubin, & Tad A. Holak. (2018). PO-432 Small molecules, peptides and antibodies – the comparison of PD-1/PD-L1 blocking potential in an in vitro immune checkpoint blockade assay. ESMO Open. 3. A400–A400. 3 indexed citations

16.

Magiera‐Mularz, Katarzyna, Łukasz Skalniak, Krzysztof M. Żak, et al.. (2017). Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint. Angewandte Chemie International Edition. 56(44). 13732–13735. 136 indexed citations

17.

Magiera‐Mularz, Katarzyna, Łukasz Skalniak, Krzysztof M. Żak, et al.. (2017). Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint. Angewandte Chemie. 129(44). 13920–13923. 5 indexed citations

18.

Skalniak, Łukasz, Krzysztof M. Żak, Katarzyna Guzik, et al.. (2017). Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 8(42). 72167–72181. 221 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact